AVGR:NSD-Avinger, Inc (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 1.14

Change

+0.05 (+4.59)%

Market Cap

USD 0.10B

Volume

4.49M

Average Target Price

USD 2.50 (+119.30%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. The company markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was founded in 2007 and is headquartered in Redwood City, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-10 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ALGN Align Technology, Inc

-43.84 (-7.33%)

USD47.35B 103.82 81.04
PODD Insulet Corporation

-7.44 (-3.18%)

USD15.51B 1,844.02 159.76
LVGO Livongo Health, Inc

N/A

USD14.20B N/A N/A
ABMD Abiomed, Inc

-14.09 (-4.75%)

USD13.44B 60.08 55.78
BRKR Bruker Corporation

-0.81 (-1.17%)

USD10.51B 52.48 26.42
IART Integra LifeSciences Holdings ..

-0.54 (-0.73%)

USD6.28B 37.24 22.75
TNDM Tandem Diabetes Care, Inc

-3.64 (-4.33%)

USD5.27B N/A N/A
SWAV ShockWave Medical, Inc

-13.07 (-8.84%)

USD5.17B N/A N/A
LIVN LivaNova PLC

-0.09 (-0.11%)

USD4.05B 77.40 N/A
WMGI Wright Medical Group N.V

N/A

USD3.90B N/A 50.67

ETFs Containing AVGR

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 159.03% 96% A 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 159.03% 96% A 98% A+
Trailing 12 Months  
Capital Gain 251.96% 92% A- 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 251.96% 92% A- 92% A-
Trailing 5 Years  
Capital Gain -99.98% 6% F N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.98% 6% F N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -59.79% 4% F N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -59.79% 4% F N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 84.48% 32% F 19% F
Risk Adjusted Return -70.77% 8% F 3% F
Market Capitalization 0.10B 28% F 21% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 0.09 81% B- 92% A-
Price/Book Ratio 8.45 42% F 20% F
Price / Cash Flow Ratio -7.00 48% F 71% C-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -190.34% 18% F 5% F
Return on Invested Capital -83.02% 27% F 9% F
Return on Assets -38.15% 22% F 8% F
Debt to Equity Ratio 71.89% 36% F 31% F
Technical Ratios  
Short Ratio 0.60 92% A- 79% C+
Short Percent 2.72% 67% D+ 57% F
Beta 1.59 30% F 25% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector